About Agios Pharmaceuticals, Inc. - Common Stock (AGIO)
Agios Pharmaceuticals is a biopharmaceutical company focused on discovering and developing innovative therapies for genetically defined diseases, particularly in the fields of oncology and rare metabolic disorders. The company leverages its expertise in cellular metabolism and its proprietary drug discovery platform to create cutting-edge treatments that target the underlying causes of these diseases. Through a commitment to advancing science and improving the lives of patients, Agios aims to address unmet medical needs and bring transformative therapies to market. Read More
Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of mixed topline results from its pivotal RISE UP Phase 3 trial for mitapivat in sickle cell disease (SCD). While the investigational therapy
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios said.
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly positive topline results from its registrational trial of ozekibart (INBRX-109) for advanced or metastatic, unresectable chondrosarcoma. This monumental achievement positions ozekibart as a potential
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or “the Company”) (NASDAQ: AGIO) for violations of the securities laws.
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
